LENZ THERAPEUTICS INC (LENZ)
Health Care · ophthalmology pharmaceuticals · NASDAQ
LENZ Therapeutics is a commercial-stage ophthalmology company marketing VIZZ, a first-of-its-kind, once-daily aceclidine-based eye drop for treating presbyopia.
What LENZ THERAPEUTICS INC does
LENZ Therapeutics is a commercial-stage pharmaceutical company focused on the development and commercialization of its proprietary eye drop therapy, VIZZ (aceclidine ophthalmic solution) 1.44%. The company's flagship product, VIZZ, is an FDA-approved, once-daily pharmacological eye drop designed to improve near vision in patients with presbyopia. LENZ markets VIZZ in the U.S. and maintains various licensing and distribution partnerships to expand its availability in international markets.
Recent developments
In July 2026, the company launched a telehealth prescribing platform and a nationwide TV advertising campaign to accelerate VIZZ adoption. In June 2026, the company secured a new commercialization partnership with Arrotex Pharmaceuticals for Australia and New Zealand and reported that Everest Medicines acquired the rights to VIZZ in Greater China from a previous licensee.
From LENZ THERAPEUTICS INC's filing of 2026-08-11.
Themes: presbyopia treatment, ophthalmology, prescription eye drops
Fundamentals
- Price$3.19 as of 2026-10-20 close
- Market cap$100M as of 2026-08-05 (share count; price 2026-10-20)
- 1-year return-91.2% 2025-10-20 close $36.31 → 2026-10-20 close $3.19
- P/En/a negative earnings
- Net margin-430.3% FY2025, SEC XBRL
- ROE-28.9% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.66 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How LENZ compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $5M | -$34M | -$32M | -$1.02 | -$39M† | $16000† |
| Q1 FY2026 2026-03-31 | $2M | -$44M | -$41M | -$1.32 | -$34M | $18000 |
| Q4 FY2025 2025-12-31 | — | -$38M† | -$36M† | -$1.20† | -$33M† | $38000† |
| Q3 FY2025 2025-09-30 | — | -$19M | -$17M | -$0.59 | -$9M† | $439000† |
| Q2 FY2025 2025-06-30 | $5M | -$17M | -$15M | -$0.53 | -$12M† | $240000† |
| Q1 FY2025 2025-03-31 | $0 | -$17M | -$15M | -$0.53 | -$16M | $110000 |
| Q4 FY2024 2024-12-31 | — | -$15M† | -$13M† | -$0.41† | -$9M† | $149000† |
| Q3 FY2024 2024-09-30 | — | -$13M | -$10M | -$0.38 | -$11M† | $186000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$24M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How LENZ THERAPEUTICS INC looks technically
LENZ THERAPEUTICS INC (LENZ) is trading 63.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 210 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It just made a new 20-day low, breaking below its recent trading range. It is 2.2% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 63.2% below its 200-day average, the long-term trend line — a long-term downtrend | -63.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.33 | $4.33 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.67 | $8.67 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 26 calendar days ago — the swings before that are what the structure reading is measured on | 26 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 4.535. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 210 trading days ago — a "death cross", a bearish long-term signal | 210 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control | 29.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30) | 31.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($3.12 to $3.91) — its "stochastic" reading is 9 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 8.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $42.98 | $42.98 |
|---|---|---|
| From the 52-week high | it is 92.6% below its 52-week high (its highest price of the past year) | -92.6% |
| Above the 52-week low | it is 2.2% above its 52-week low (its lowest price of the past year) | +2.2% |
| Below the 52-week high | it is 92.6% below its highest point of the past year | 92.6% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $238.00 (set on 2021-06-30) | $238.00 |
| Given back of the 52-week move | over the past year its closes ranged ($3.19 to $41.85), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $27.08 to $28.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 98.7% below its all-time high | -98.7% |
| Nearest price level | it is trading 42.4% below a resistance level at $4.54 — a price it turned at twice since 2026-08-13, most recently on 2026-08-24. Since 2024-10-21 it has 0 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +42.4% |
| All-time low | its lowest closing price on record is $3.12 (set on 2026-10-20) | $3.12 |
| Above the all-time low | it is 2.2% above its all-time low | +2.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 76% of it) | 24th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2435 between its high and its low — about 7.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2435 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.19 and $4.04 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.19 – $3.62 – $4.04 |
| Typical daily range (% of price) | its price moves about 7.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.6% |
| Stretch from the 200-day average | it is trading 22.5 daily ranges below its 200-day average price (63.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 22.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.06× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.6% since the prior reading | -0.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.9% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-09-17 has been "filled" 23 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 23 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 22.6 percentage points (the stock lost 21.6% while the market gained 1.0%) | -22.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 39.3 percentage points (the stock lost 35.7% while the market gained 3.6%) | -39.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 77.0 percentage points (the stock lost 68.5% while the market gained 8.5%) | -77.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 105.8 percentage points (the stock lost 91.2% while the market gained 14.6%) | -105.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 41% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.0% of the share price. | -40.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 65% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $9.02 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -64.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 26% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.31 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -26.0% |
Price levels it has turned at before
LENZ last closed at $3.19 on 2026-10-20. Since 2024-10-21 it has turned at 0 prices below its last close and 8 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.54 | Resistance | 42.4% above the last close | turned there twice · 2026-08-13 to 2026-08-24 |
| $6.17 | Resistance | 93.6% above the last close | turned there twice · 2026-07-08 to 2026-07-28 |
| $21.16 | Resistance | 563.2% above the last close | turned there three times · 2025-01-16 to 2025-11-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $4.54.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $4.16 and $4.54 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 6 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · Near the all-time low | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.57 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$23.86 range $7.00 – $60.00; median $10.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LENZ
- Consensus EPS estimate-$0.955 next reporting period, as of 2026-10-17
- Estimate change, 30 days+$0.02167 from -$0.9767, on 2026-09-12, 35-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a single product (VIZZ) for all revenue and growth prospects.","History of significant losses and limited operating history as a commercial company.","Potential failure to achieve sufficient market acceptance or competition from cheaper, branded, generic, or off-label alternatives."]
What changed in the latest 10-Q
AI-assisted comparison of LENZ's 10-Q filed 2026-08-11 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer MD&A (filed 2026-08-11) adds: 'Beginning in July 2026, VIZZ became available via a telehealth platform, providing the convenience of an integrated online evaluation by independent licensed ECPs, ePharmacy prescription fulfillment and home delivery.'
- Newer MD&A (filed 2026-08-11) adds a 'Table of Contents' page break heading after the Overview section.
- Removed:
- Older MD&A (filed 2026-05-11) includes: 'We believe that our existing cash, cash equivalents and marketable securities as of March 31, 2026 will allow us to continue to commercialize VIZZ, and we anticipate will be sufficient to fund the Company to positive operating cash flow.' This statement is removed in the newer filing.
- Older MD&A (filed 2026-05-11) includes: 'while we believe that our existing cash, cash equivalents and marketable securities as of March 31, 2026 will fund the Company to positive operating cash flow,' which is removed in the newer filing.
- Older MD&A (filed 2026-05-11) includes a 'Table of Contents' page break heading between the Financial Overview first paragraph and its continuation.
- Reworded:
- Date reference in Financial Overview changed from 'As of March 31, 2026' (older, filed 2026-05-11) to 'As of June 30, 2026' (newer, filed 2026-08-11).
- Cash balance changed from '$258.4 million' (older, as of March 31, 2026) to '$220.0 million' (newer, as of June 30, 2026).
- Accumulated deficit changed from '$268.6 million' (older, as of March 31, 2026) to '$300.5 million' (newer, as of June 30, 2026).
- Sales Agreement capacity language changed from 'As of March 31, 2026, the Company had no remaining capacity remaining under the Sales Agreement.' (older) to 'As of June 30, 2026, the Company had no remaining capacity remaining under the Sales Agreement.' (newer).
- License agreement heading changed from 'CORXEL License and Collaboration Agreement' (older) to 'Everest Medicines License and Collaboration Agreement' (newer).
- License description changed: older filing (filed 2026-05-11) refers to 'CORXEL Pharmaceuticals (formerly known as Ji Xing Pharmaceuticals Hong Kong Limited)' and 'the CORXEL License formerly referred to as the Ji Xing License'; newer filing (filed 2026-08-11) refers to 'CORXEL Pharmaceuticals (formerly known as Ji Xing Pharmaceuticals Hong Kong Limited)' and 'the Everest License formerly referred to as the CORXEL License and the Ji Xing License'.
- Product distribution partner terminology changed from 'e-pharmacy partner' (older) to 'ePharmacy partner' (newer).
- Notes:
- This comparison is AI-assisted and covers only the provided text excerpts; it is not a complete review of the full MD&A sections from either filing.
Risk Factors
- Added:
- Newer filing includes net loss figures for the six months ended June 30, 2026 and 2025: $73.4 million and $29.5 million, respectively (filed 2026-08-11).
- Newer filing states accumulated deficit as of June 30, 2026 was $300.5 million (filed 2026-08-11).
- Removed:
- Older filing included net loss figures for the three months ended March 31, 2026 and 2025: $41.5 million and $14.6 million, respectively (filed 2026-05-11).
- Older filing stated accumulated deficit as of March 31, 2026 was $268.6 million (filed 2026-05-11).
- Reworded:
- Newer filing changed the three-month net loss figures to $31.9 million and $14.9 million for the three months ended June 30, 2026 and 2025, respectively, from the older filing's figures of $41.5 million and $14.6 million for the three months ended March 31, 2026 and 2025 (filed 2026-08-11 vs 2026-05-11).
- Newer filing changed 'create additional infrastructure to support our operations as a public company and our product development and commercialization efforts' to 'maintain or increase our infrastructure to support our operations as a public company and our product development and commercialization efforts' (filed 2026-08-11 vs 2026-05-11).
- Newer filing ends the last bullet list item with 'maintain, protect, and expa' whereas the older filing continues with 'maintain, protect, and expand our intellectual property portfolio;' and 'initiate additional clinical and other studies for any future' (filed 2026-08-11 vs 2026-05-11).
- Notes:
- The newer filing text is truncated at 'maintain, protect, and expa' and the older filing text is truncated at 'initiate additional clinical and other studies for any future', so comparisons after those truncation points cannot be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of LENZ within a 30-day window between 2026-03-27 and 2026-03-27. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-03-27. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LENZ's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LENZ as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,489,586
- Reported value $42,540,844
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LENZ's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LENZ had 10,560,869 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
LENZ had 33.6% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.78 days to cover at the same settlement.
- Reported short interest (shares) 10,560,869
- Short interest (% of shares outstanding) 33.6%
- Prior settlement (shares) 10,629,972
- Reported change -0.65%
- Days to cover (reported) 13.78
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Orasis Pharmaceuticals
- Amneal Pharmaceuticals (AMRX)
- Tenpoint Therapeutics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LENZ vs…
LENZ THERAPEUTICS INC is found in…
LENZ ranks in…
Frequently asked questions
What does LENZ THERAPEUTICS INC (LENZ) do?
LENZ Therapeutics is a commercial-stage pharmaceutical company focused on the development and commercialization of its proprietary eye drop therapy, VIZZ (aceclidine ophthalmic solution) 1.44%. The company's flagship product, VIZZ, is an FDA-approved, once-daily pharmacological eye drop designed to improve near vision in patients with presbyopia. LENZ markets VIZZ in the U.S. and maintains various licensing and distribution partnerships to expand its availability in international markets.
What sector is LENZ THERAPEUTICS INC (LENZ) in?
LENZ THERAPEUTICS INC (LENZ) is classified in the Health Care sector. Its industry is ophthalmology pharmaceuticals. It trades on NASDAQ.
Who are LENZ THERAPEUTICS INC's (LENZ) competitors?
Notable peers of LENZ THERAPEUTICS INC (LENZ) include AbbVie, Orasis Pharmaceuticals, Amneal Pharmaceuticals and Tenpoint Therapeutics. This peer set is informational only — not financial advice.
Is LENZ THERAPEUTICS INC (LENZ) overbought or oversold right now?
LENZ THERAPEUTICS INC (LENZ) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 31, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LENZ come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.